Mangrove Partners purchased a new stake in shares of Aldeyra Therapeutics Inc (NASDAQ:ALDX) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 164,384 shares of the biotechnology company’s stock, valued at approximately $1,118,000. Mangrove Partners owned 0.86% of Aldeyra Therapeutics as of its most recent SEC filing.
Several other institutional investors have also recently added to or reduced their stakes in the business. Perceptive Advisors LLC grew its stake in shares of Aldeyra Therapeutics by 6.9% during the 3rd quarter. Perceptive Advisors LLC now owns 3,085,458 shares of the biotechnology company’s stock valued at $22,215,000 after acquiring an additional 200,000 shares during the period. Sphera Funds Management LTD. grew its stake in shares of Aldeyra Therapeutics by 19.2% during the 3rd quarter. Sphera Funds Management LTD. now owns 1,044,131 shares of the biotechnology company’s stock valued at $7,518,000 after acquiring an additional 168,200 shares during the period. 683 Capital Management LLC grew its stake in shares of Aldeyra Therapeutics by 59.1% during the 3rd quarter. 683 Capital Management LLC now owns 835,514 shares of the biotechnology company’s stock valued at $6,016,000 after acquiring an additional 310,421 shares during the period. Bank of New York Mellon Corp bought a new position in shares of Aldeyra Therapeutics during the 3rd quarter valued at approximately $134,000. Finally, Woodstock Corp grew its stake in shares of Aldeyra Therapeutics by 20.4% during the 4th quarter. Woodstock Corp now owns 58,243 shares of the biotechnology company’s stock valued at $396,000 after acquiring an additional 9,850 shares during the period. Institutional investors and hedge funds own 51.17% of the company’s stock.
NASDAQ ALDX traded down $0.50 during trading hours on Monday, reaching $7.00. The company’s stock had a trading volume of 89,374 shares, compared to its average volume of 103,608. The company has a current ratio of 20.35, a quick ratio of 20.35 and a debt-to-equity ratio of 0.02. Aldeyra Therapeutics Inc has a 1 year low of $3.80 and a 1 year high of $11.90. The stock has a market cap of $147.49, a PE ratio of -5.00 and a beta of 0.56.
Aldeyra Therapeutics (NASDAQ:ALDX) last posted its quarterly earnings results on Thursday, March 29th. The biotechnology company reported ($0.36) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.32) by ($0.04). analysts forecast that Aldeyra Therapeutics Inc will post -1.43 EPS for the current fiscal year.
ALDX has been the subject of a number of recent research reports. Zacks Investment Research upgraded Aldeyra Therapeutics from a “hold” rating to a “buy” rating and set a $7.50 price objective for the company in a research note on Tuesday, January 2nd. Seaport Global Securities reiterated a “buy” rating on shares of Aldeyra Therapeutics in a research note on Thursday, March 1st. Canaccord Genuity reiterated a “buy” rating and set a $27.00 price objective on shares of Aldeyra Therapeutics in a research note on Tuesday, March 13th. Cantor Fitzgerald set a $23.00 price objective on Aldeyra Therapeutics and gave the company a “buy” rating in a research note on Thursday. Finally, ValuEngine upgraded Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $16.93.
TRADEMARK VIOLATION NOTICE: “Mangrove Partners Takes Position in Aldeyra Therapeutics Inc (ALDX)” was first reported by Enterprise Leader and is the sole property of of Enterprise Leader. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://theenterpriseleader.com/2018/04/02/mangrove-partners-invests-1-12-million-in-aldeyra-therapeutics-inc-aldx-stock.html.
Aldeyra Therapeutics Company Profile
Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.